Earnings results for C4 Therapeutics (NASDAQ:CCCC)
C4 Therapeutics, Inc. is estimated to report earnings on 03/11/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.51.
Analyst Opinion on C4 Therapeutics (NASDAQ:CCCC)
3 Wall Street analysts have issued ratings and price targets for C4 Therapeutics in the last 12 months. Their average twelve-month price target is $39.50, predicting that the stock has a possible downside of 6.24%. The high price target for CCCC is $45.00 and the low price target for CCCC is $34.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
C4 Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $39.50, C4 Therapeutics has a forecasted downside of 6.2% from its current price of $42.13. C4 Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: C4 Therapeutics (NASDAQ:CCCC)
C4 Therapeutics does not currently pay a dividend. C4 Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: C4 Therapeutics (NASDAQ:CCCC)
In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.
Earnings and Valuation of C4 Therapeutics (NASDAQ:CCCC
Earnings for C4 Therapeutics are expected to grow in the coming year, from ($19.62) to ($2.40) per share.
More latest stories: here